Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s most diversified healthcare leaders in 2025, advancing a series of product launches, label expansions, and commercial scale-ups across oncology, immunology, neuroscience, cardiovascular disease, and medical technology. The year marked a shift from portfolio restructuring to execution-driven growth, following the full separation of its consumer health business.
Oncology Portfolio: Flagship Brands and Next-Generation Assets
DARZALEX® — Multiple Myeloma
Condition: Newly diagnosed and relapsed/refractory multiple myeloma
In 2025, DARZALEX continued to expand its global footprint through earlier-line adoption and combination regimens, maintaining its status as J&J’s largest oncology growth driver.
Strategic Impact:
DARZALEX’s broad label and durable efficacy underpin J&J’s long-term hematology leadership, supporting sustained premium oncology revenues.
CARVYKTI® — Cell Therapy
Condition: Relapsed or refractory multiple myeloma
J&J advanced commercial scale-up for CARVYKTI in 2025, supported by manufacturing expansion and growing confidence in CAR-T adoption.
Strategic Impact:
Cell therapy remains a strategic frontier, positioning J&J at the high end of personalized oncology innovation.
Immunology Portfolio: Broad-Based Franchise Strength
STELARA® — Immune-Mediated Diseases
Conditions: Psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis
While facing biosimilar pressure, STELARA remained a meaningful contributor in 2025, supported by global markets and entrenched prescriber familiarity.
TREMFYA® — IL-23 Inhibition
Conditions: Psoriasis, psoriatic arthritis
TREMFYA continued to gain share in 2025, benefiting from expanded data and physician confidence in IL-23-targeted therapies.
Strategic Impact:
TREMFYA represents J&J’s next-generation immunology growth engine, supporting franchise continuity beyond STELARA.
Neuroscience and Specialty Medicine
SPRAVATO® — Treatment-Resistant Depression
Condition: Major depressive disorder
In 2025, SPRAVATO sustained growth through expanded access and growing real-world evidence supporting its differentiated mechanism.
Strategic Impact:
Neuroscience assets provide specialty revenue streams with increasing mental health prioritization globally.
Cardiovascular and Pulmonary Disease
OPSUMIT® / UPTRAVI® — Pulmonary Arterial Hypertension
Condition: Pulmonary arterial hypertension
J&J continued to advance its pulmonary hypertension portfolio in 2025, maintaining leadership in a high-value rare cardiovascular market.
Strategic Impact:
Rare cardiovascular diseases offer high-margin, durable growth opportunities aligned with J&J’s specialty focus.
MedTech Portfolio: Innovation at Scale
In 2025, Johnson & Johnson MedTech strengthened its position across:
- Robotic surgery
- Electrophysiology
- Orthopedics and vision care
Digital surgery platforms, AI-enabled imaging, and data-driven procedural planning remained key innovation pillars.
Strategic Impact:
MedTech provides technology-driven, recurring revenue streams, balancing pharmaceutical cyclicality.
Digital, Data, and AI Enablement
Across pharmaceuticals and MedTech, J&J expanded the use of AI and advanced analytics in 2025 to:
- Accelerate drug discovery
- Improve clinical trial execution
- Enhance surgical precision and outcomes
Strategic Impact:
AI integration strengthens J&J’s ability to operate as a science-and-technology-driven healthcare enterprise.
Looking Ahead: 2026 and Beyond
Johnson & Johnson enters 2026 with:
- A diversified growth portfolio
- Leadership across oncology, immunology, neuroscience, cardiovascular disease, and MedTech
- Strong balance sheet flexibility for continued investment and partnerships
The company’s 2025 execution highlights its ability to scale innovation across multiple healthcare verticals simultaneously.
Conclusion
Johnson & Johnson’s 2025 performance underscores the strength of its diversified, innovation-led strategy. With flagship oncology brands, resilient immunology assets, and a technology-driven MedTech platform, J&J is positioned to deliver sustainable growth and clinical impact well into the next decade.
By